

Recipharm joins the AMR Industry Alliance

Global contract development and manufacturing organisation (CDMO) Recipharm, has announced that it is joining the AMR Industry Alliance as part of its ambition to contribute to exploring solutions to tackle growing concerns around antimicrobial resistance (AMR).

The AMR Industry Alliance is one of the largest coalitions set up to provide sustainable solutions to curb AMR. With over 100 members, including biotechnology, diagnostics, generics and pharmaceutical research organisations and associations, the alliance facilitates collaboration and informs external stakeholders about new developments in the field of AMR.

Recipharm's membership is the latest step in the company's ongoing efforts to engage with other organisations working to tackle AMR.

Erik Haeffler, VP of Manufacturing Services and Head of Sustainability at Recipharm said, "AMR is currently one of the most serious health concerns worldwide. At Recipharm, we manufacture antibiotics in Sweden, Italy and India so it's important that we get involved in developing solutions to combat AMR. Joining the AMR Industry Alliance was the next natural step for us to take our work on AMR to the next level and allow us to engage with other stakeholders on the subject."

As well as joining the AMR Industry Alliance, Recipharm is also involved in a number of other initiatives focused on AMR. For example, the multisector collaboration platform, PLATINEA, led by Uppsala University designed to find ways to preserve and enhance the value of existing antibiotics and the Reducing Emissions from Antibiotic Production (REAP) project which was launched at World Water Week 2019 in Stockholm by the Stockholm International Water Institute (SIWI).

Steve Brooks, Chair of the Manufacturing Working Group at the AMR Industry Alliance said, "We welcome Recipharm as a new member of the alliance. In recent years we've seen more and more companies recognising and addressing AMR and we're delighted to see a leading CDMO like Recipharm committing to the objectives of the AMR Industry Alliance, including minimizing antibiotic emissions from the manufacturing supply chain".

AMR is recognised as a serious industry concern. The WHO, G7, G20 and many world leaders have acknowledged the growing dangers AMR presents and have called for concerted action from all relevant parties to work on solutions and their implementation.

Erik Haeffler continued, "In addition to allowing us to further explore solutions to AMR, the alliance also presents us with a framework for reducing the environmental risk of manufacturing antibiotics using risk assessments and a list of science-driven discharge concentration targets."

"We're confident the alliance will allow us to continue working with experts in the field of AMR and take positive steps towards developing potential solutions."



Contact information

Erik Haeffler, Vice President Manufacturing Services & Head of Sustainability, erik.haeffler@recipharm.com, + 46 8 6025 285

For media enquiries, please contact Kate Hindhaugh at ramarketing: kate@ramarketingpr.com, + 44 (0)191 222 1242, ramarketingpr.com, Twitter: @ramarketingpr, Facebook: /ramarketingpr, LinkedIn: /ramarketing

About Recipharm

Recipharm is a leading Contract Development and Manufacturing Organisation (CDMO) in the pharmaceutical industry employing around 6,000 employees. Recipharm offers manufacturing services of pharmaceuticals in various dosage forms, production of clinical trial material and APIs, and pharmaceutical product development. Recipharm manufactures several hundred different products to customers ranging from big pharma to smaller research and development companies. Recipharm's turnover is approximately SEK 6.4 billion and the company operates development and manufacturing facilities in France, Germany, India, Israel, Italy, Portugal, Spain, Sweden, the UK and the US and is headquartered in Stockholm, Sweden. The Recipharm B-share (RECI B) is listed on Nasdaq Stockholm.

For more information on Recipharm and our services, please visit www.recipharm.com